Skip to main content

Table 1 Tumor molecular and pathological features in colorectal carcinomas

From: Biomarker correlation network in colorectal carcinoma by tumor anatomic location

Biomarker Status measured % or mean (SD) of the status in proximal colon (n = 690)a % or mean (SD) of the status in distal colorectum
(n = 690)a
% availability in proximal colon (n = 690) % availability in distal colorectum (n = 690)
Somatic oncogenic mutations
BRAF Mutation 25.1% 5.6% 86.1% 87.4%
KRAS Mutation 43.0% 36.6% 86.2% 87.5%
PIK3CA Mutation 18.4% 14.5% 79.7% 80.9%
Methylation status
MLH1 Methylation 25.3% 3.9% 83.5% 82.5%
CDKN2A Methylation 44.3% 21.8% 83.5% 82.5%
CACNA1G Methylation 40.3% 9.9% 83.5% 82.3%
CRABP1 Methylation 52.8% 20.9% 83.5% 82.5%
IGF2 Methylation 44.3% 12.1% 83.5% 82.5%
NEUROG1 Methylation 53.1% 21.0% 83.5% 82.3%
RUNX3 Methylation 40.1% 8.8% 83.5% 82.5%
SOCS1 Methylation 30.4% 7.9% 83.3% 82.5%
 LINE-1 Degree of methylation (%) 64.7 (SD, 9.7) 62.6 (SD, 9.9) 85.1% 84.5%
IGF2 DMR0 Methylation 22.0% 29.6% 65.1% 65.2%
Microsatellite instability (MSI)
 MSI MSI-high 28.2% 4.9% 85.9% 85.7%
Protein expression
 CDH1 Loss 52.6% 50.9% 44.9% 42.5%
 CDKN1A Loss 72.3% 89.2% 52.8% 55.2%
 CDKN1B Loss 47.9% 34.8% 51.7% 53.8%
 CDKN2A Loss 35.3% 17.9% 46.8% 47.8%
 CDX2 Loss 36.6% 17.2% 43.2% 39.7%
 MGMT Loss 34.7% 38.9% 42.6% 43.9%
 AURKA Overexpression 22.2% 14.3% 32.6% 28.4%
 CCND1 Overexpression 82.6% 73.5% 64.9% 65.5%
 CD274 Overexpression 85.6% 83.7% 43.2% 40.0%
 CDK8 Overexpression 72.6% 69.4% 30.7% 26.5%
 CTNNB1 (nuclear) Overexpression 32.7% 58.2% 75.8% 74.2%
 CTSB Overexpression 82.7% 82.9% 45.2% 42.3%
 DNMT3B Overexpression 19.7% 10.3% 45.5% 49.3%
 EPAS1 Overexpression 47.0% 44.5% 46.2% 42.0%
 FASN Overexpression 61.1% 60.0% 64.8% 65.9%
 HGF Overexpression 45.8% 47.9% 39.6% 37.2%
 HIF1A Overexpression 17.0% 20.1% 47.7% 42.6%
 IGF2BP3 Overexpression 36.8% 32.7% 43.8% 41.2%
 IRS1 Overexpression 29.5% 30.6% 44.6% 41.7%
 IRS2 Overexpression 31.6% 33.2% 44.9% 41.9%
 PPARG Overexpression 24.1% 19.2% 33.6% 29.4%
 PTGER2 Overexpression 27.8% 26.3% 45.8% 41.3%
 PTGS2 Overexpression 53.5% 69.7% 81.7% 79.9%
 SIRT1 Overexpression 38.6% 37.9% 39.4% 35.9%
 STAT3 Overexpression 54.7% 54.0% 46.4% 43.2%
 TP53 Overexpression 33.0% 53.2% 66.7% 67.2%
 VDR Overexpression 37.0% 38.2% 47.4% 42.5%
 YAP1 (cytoplasmic) Overexpression 21.3% 17.7% 44.2% 41.0%
 JC Virus T-Antigen (JCVT) Overexpression 28.4% 40.7% 43.9% 47.7%
Immune reactions
 Peritumoral lymphocytic reaction Greater reaction 19.4% 12.9% 95.8% 91.2%
 Intratumoral periglandular reaction Greater reaction 17.2% 9.0% 95.9% 91.6%
 Tumor infiltrating lymphocytes (TIL) Greater reaction 16.3% 4.4% 95.9% 91.6%
 Crohn’s-like reaction Greater reaction 9.9% 5.0% 80.4% 73.2%
 CD3+ in cancer area Density (cells/mm2) 716.6 (SD, 1501.8) 696.5 (SD, 1560.7) 47.1% 42.9%
 CD8+ in cancer area Density (cells/mm2) 814.7 (SD, 1741.0) 700.9 (SD, 1582.1) 46.7% 41.7%
 CD45RO+ in cancer area Density (cells/mm2) 711.4 (SD, 1113.4) 634.4 (SD, 1244.7) 48.1% 43.6%
 FOXP3+ in cancer area Density (cells/mm2) 40.0 (SD, 47.0) 35.2 (SD, 37.9) 45.2% 41.9%
miRNA expression
 MIR21 Normalized expression level 8.3 (SD, 13.0) 5.6 (SD, 4.0) 53.2% 48.6%
 MIR155 Normalized expression level 0.01 (SD, 0.01) 0.005 (SD, 0.006) 53.2% 48.6%
Microorganism
Fusobacterium nucleatum Presence 16.0% 9.1% 71.7% 67.1%
  1. aPercentage (%) indicates the proportion of the status measure for a binary biomarker, and the mean (SD) was calculated for a continuous biomarker
  2. SD standard deviation